AUS
NZ
UK
CA
USA
IND
Highlights
- FDA agrees to review PAS for reducing patient numbers in NEPHRO CRRT study.
- Two protocol changes approved to accelerate enrollment, improving study efficiency.
- Talphera maintains breakthrough designation status for nafamostat in CRRT.
Talphera (NASDAQ:TLPH), a clinical-stage biopharmaceutical company focused on developing innovative therapies, has announced significant developments in its NEPHRO CRRT clinical study following a recent meeting with the U.S. Food and Drug Administration (FDA). The FDA has agreed to review a Prior Approval Supplement (PAS) for reducing the number of patients involved in the study, with the submission expected to be completed within the week. The FDA’s review process will take up to 30 days.
Key Protocol Changes to Expedite Enrollment
In addition to the PAS review, the FDA approved two important protocol changes that will help expedite patient enrollment in the NEPHRO CRRT study. The first change allows for the inclusion of patients who are undergoing continuous renal replacement therapy (CRRT) for more than 48 hours, broadening the pool of eligible participants. The second change permits the inclusion of heparin-tolerant patients at specific institutions, which could further streamline enrollment. These changes will be implemented immediately via a five-day protocol amendment notice, with no additional FDA review required.
These regulatory approvals are expected to significantly accelerate the enrollment process, bringing the company closer to completing the NEPHRO CRRT study by the end of 2025. The study focuses on nafamostat, an alternative anticoagulant for CRRT patients, which has already been granted breakthrough designation status by the FDA.
Breakthrough Designation and Development of Nafamostat
Nafamostat’s breakthrough designation status underscores its potential as an important treatment option for CRRT patients. This designation allows Talphera to work closely with the FDA to expedite the development process and gain regulatory approval more quickly. Nafamostat is being developed as an alternative to heparin, which is commonly used in CRRT but has certain limitations.
The company’s goal is to complete the NEPHRO CRRT study by the end of this year, which will provide the necessary data to support nafamostat’s potential approval as a new treatment option for CRRT patients.
